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OBJECTIVE:
 
 Studies using claims databases usually es-
tablish initial diagnosis for a disease by requiring subjects
to be disease-free for some period of time before inclusion
in the study. This time period should be stringent enough
to minimize misclassification of cases, but liberal enough
to ensure an adequate sample size. This study evaluated
the change in study sample size when the time period that
subjects were required to be disease-free (disease-free
time period) was varied.
METHODS: Patients diagnosed with hypertension (ICD-
9-CM 410) in the South Carolina Medicaid population in
1995 (n  20,829) were followed back in time (1992–
1994) to determine the change in sample size when the
disease-free time period was varied from 6 months to 3
years. All patients were required to be eligible for at least
11 months in each year of interest.
RESULTS: The table below shows percent decreases in
sample size when disease-free time periods were varied.
The disease-free sample size decreased by approximately
50% in the 12-month period following patient identifica-
tion. It continued to decrease at a lower rate as the dis-
ease-free time period was increased to 18 months and ta-
pered off thereafter.
CONCLUSIONS: Studies using disease-free time periods
of less than 12–18 months may include 10–20% of sub-
jects identified that are not actually initially diagnosed
patients. This may introduce potential bias if researchers
think they are analyzing initially diagnosed subjects.
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Increasing demand for health economics (HE) means that
HE information on pharmaceutical interventions is be-
coming more widely used in promotion.
OBJECTIVE: To identify and assess the current legisla-
tive structure relating to the inclusion of HE data in the
advertising of medicines in the European Union (EU).
METHOD: A review of published literature and EU leg-
islation.
RESULTS: Advertising and promotion of medicinal
products for human use is regulated by the EC directive
92/28/EEC. In addition, member states have their own
codes of practice, some regulate pharmaceutical advertis-
ing by tribunals (e.g., Germany), others by self-regulating
bodies (e.g., the ABPI in the UK), and some by the health
authority (e.g., Agence de Medicament in France). All
embody the principles and standards from 92/28/EEC,
whereby advertising should encourage rational use of the
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Years of interest
Pt # eligible for 11
mo in each year
of interest
% decrease in sample size
6 mo 12 mo 18 mo 24 mo 30 mo 36 mo
1994 13202 51.53 61.69 NA NA NA NA
1993 & 1994 10512 52.63 63.57 70.41 73.77 NA NA
1992, 1993, & 1994 8634 52.95 63.93 70.81 74.18 76.11 77.43
